Table 1.

Pathological complete response (pCR) rates and its association to clinicopathological variables

Variable	Total number	Subgroup	CR		RD		P-value	Chi-square value
			Number	%	Number	%
Age group	162	<48 years (48.15%)	24	30.77	54	69.23	0.174	1.848
		≥48 years (51.85%)	17	20.24	67	79.76
Tumor stage	158	T1 and T2 (41.77%)	19	28.78	47	71.22	0.5064	0.442
		T3 and T4 (58.23%)	21	13.41	71	86.59
Nodal involvement	155	Yes (73.55%)	25	21.93	89	78.07	0.4643	0.535
		No (26.45%)	12	29.27	29	70.73
Grade	144	3 (50.69%)	20	27.4	53	72.6	0.044 (chi-square test for trend)	4.062 (chi-square value for trend)
		2 (40.97%)	12	20.34	47	79.66
		1 (8.33%)	0	0	12	100
Hormone receptor	159	Positive (75.47%)	28	23.33	92	76.67	0.6891	0.16
		Negative (24.53%)	11	28.2	28	71.8
ER	159	Positive (74.84%)	27	22.69	92	77.31	0.47	0.515
		Negative (25.16%)	12	30	28	70
PR	159	Positive (49.69%)	12	15.19	67	84.81	0.01	6.428
		Negative (50.31%)	27	33.75	53	66.25
ER/PR	159	ER and PR positive (48.43%)	11	14.28	66	85.72	0.0087 (chi-square test for trend P=0.03)	9.495 (chi-square value for trend 4.69)
		ER/PR positive (27.67%)	17	38.64	27	61.36
		ER and PR negative (23.9%)	11	28.95	27	71.05
Allred score ER	159	ER 0–2	12	30	28	70	0.003	11.89
		ER 3–5	10	52.63	9	47.37
		ER 6–8	15	16.48	76	83.51
Allred score PR	159	PR 0–2	28	35.44	51	64.56	0.005	10.46
		PR 3–5	2	11.11	16	88.89
		PR 6–8	7	13.2	46	86.8
HER2 neu	153	Positive (40.52%)	16	25.8	46	74.2	0.85	0.04
		Negative (59.48%)	21	23.07	70	76.93
Ki-67	120	Low (29.17%)	6	17.14	29	82.86	0.36	0.84
		High (70.83%)	23	27.06	62	76.94
Molecular subtype	140	Luminal A (15.7%)	3	13.64	19	86.36	0.51 (chi-square test for trend P=0.15)	2.34 (chi-square value for trend 2.03)
		Luminal B (55.7%)	19	24.36	59	75.64
		HER2 enriched (13.6%)	5	26.31	14	73.69
		Triple negative (15.7%)	7	33.33	14	66.67

Abbreviations: CR, complete response; ER, estrogen receptor; PR, progesterone receptor; RD, residual disease.